LFA-1 integrin antibodies inhibit leukocyte α4β1-mediated adhesion by intracellular signaling

Blood

Volumn 128, Issue 9, 2016, Pages 1270-1281

  Grönholm, Mikaela ^a   Jahan, Farhana ^a   Bryushkova, Ekaterina A ^a   Madhavan, Sudarrshan ^a   Aglialoro, Francesca ^a   Hinojosa, Laura Soto ^a   Uotila, Liisa M ^a   Gahmberg, Carl G ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; LEUKOCYTE ALPHA 4 BETA 1; LYMPHOCYTE ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 4;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING SITE; CELL ADHESION; CONTROLLED STUDY; DEPHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; CELL LINE; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; LEUKOCYTE; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIBODIES; CELL ADHESION; CELL LINE; HUMANS; INTEGRIN ALPHA4BETA1; LEUKOCYTES; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 85019767665     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-705160     Document Type: Article

References (47)

1. Chigaev A, Sklar LA. Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion. Front Immunol. 2012;3(August):242.
2. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76(2):301-314.
3. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;67(6):1033-1036.
4. Gahmberg CG, Tolvanen M, Kotovuori P. Leukocyte adhesion-structure and function of human leukocyte beta2-integrins and their cellular ligands. Eur J Biochem. 1997;245(2):215-232.
5. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346(6283):425-434.
6. Luo B-H, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:619-647.
7. Gahmberg CG, Fagerholm SC, Nurmi SM, Chavakis T, Marchesan S, Grönholm M. Regulation of integrin activity and signalling. Biochim Biophys Acta. 2009;1790(6):431-444.
8. Hogg N, Patzak I, Willenbrock F. The insider's guide to leukocyte integrin signalling and function. Nat Rev Immunol. 2011;11(6):416-426.
9. Legate KR, Fässler R. Mechanisms that regulate adaptor binding to beta-integrin cytoplasmic tails. J Cell Sci. 2009;122(Pt 2):187-198.
10. Takala H, Nurminen E, Nurmi SM, et al. Beta2 integrin phosphorylation on Thr758 acts as a molecular switch to regulate 14-3-3 and filamin binding. Blood. 2008;112(5):1853-1862.
11. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science. 1998;279(5349):381-384.
12. van Kooyk Y, van de Wiel-van Kemenade E, Weder P, Huijbens RJ, Figdor CG. Lymphocyte function-associated antigen 1 dominates very late antigen 4 in binding of activated T cells to endothelium. J Exp Med. 1993;177(1):185-190.
13. Uotila LM, Jahan F, Soto Hinojosa L, Melandri E, Grönholm M, Gahmberg CG. Specific phosphorylations transmit signals from leukocyte β2 to β1 integrins and regulate adhesion. J Biol Chem. 2014;289(46):32230-32242.
14. Grönholm M, Jahan F, Marchesan S, et al. TCRinduced activation of LFA-1 involves signaling through Tiam1. J Immunol. 2011;187(7): 3613-3619.
15. Nurmi SM, Autero M, Raunio AK, Gahmberg CG, Fagerholm SC. Phosphorylation of the LFA-1 integrin beta2-chain on Thr-758 leads to adhesion, Rac-1/Cdc42 activation, and stimulation of CD69 expression in human T cells. J Biol Chem. 2007;282(2):968-975.
16. Fagerholm SC, Hilden TJ, Nurmi SM, Gahmberg CG. Specific integrin α and β chain phosphorylations regulate LFA-1 activation through affinity-dependent and -independent mechanisms. J Cell Biol. 2005;171(4):705-715.
17. Nortamo P, Patarroyo M, Kantor C, Suopanki J, Gahmberg CG. Immunological mapping of the human leucocyte adhesion glycoprotein gp90 (CD18) by monoclonal antibodies. Scand J Immunol. 1988;28(5):537-546.
18. Weber KS, York MR, Springer TA, Klickstein LB. Characterization of lymphocyte functionassociated antigen 1 (LFA-1)-deficient T cell lines: the alphaL and beta2 subunits are interdependent for cell surface expression. J Immunol. 1997; 158(1):273-279.
19. Fagerholm S, Morrice N, Gahmberg CG, Cohen P. Phosphorylation of the cytoplasmic domain of the integrin CD18 chain by protein kinase C isoforms in leukocytes. J Biol Chem. 2002;277(3): 1728-1738.
20. Day ES, Osborn L, Whitty A. Effect of divalent cations on the affinity and selectivity of alpha4 integrins towards the integrin ligands vascular cell adhesion molecule-1 and mucosal addressin cell adhesion molecule-1: Ca2+ activation of integrin alpha4beta1 confers a distinct ligand specificity. Cell Commun Adhes. 2002;9(4):205-219.
21. Porter JC, Hogg N. Integrin cross talk: activation of lymphocyte function-associated antigen-1 on human T cells alters α4β1- and α5β1-mediated function. J Cell Biol. 1997;138(6):1437-1447.
22. Kremer KN, Clift IC, Miamen AG, et al. Stromal cell-derived factor-1 signaling via the CXCR4-TCR heterodimer requires phospholipase C-β3 and phospholipase C-γ1 for distinct cellular responses. J Immunol. 2011;187(3):1440-1447.
23. van Kooyk Y, Figdor CG. Avidity regulation of integrins: the driving force in leukocyte adhesion. Curr Opin Cell Biol. 2000;12(5):542-547.
24. García-Bernal D, Wright N, Sotillo-Mallo E, et al. Vav1 and Rac control chemokine-promoted T lymphocyte adhesion mediated by the integrin alpha4beta1. Mol Biol Cell. 2005;16(7): 3223-3235.
25. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev. 2002;22(2):146-167.
26. Hilden TJ, Nurmi SM, Fagerholm SC, Gahmberg CG. Interfering with leukocyte integrin activation-a novel concept in the development of antiinflammatory drugs. Ann Med. 2006;38(7): 503-511.
27. May AE, Neumann FJ, Schömig A, Preissner KT. VLA-4 (alpha(4)beta(1)) engagement defines a novel activation pathway for beta(2) integrindependent leukocyte adhesion involving the urokinase receptor. Blood. 2000;96(2):506-513.
28. Chan JR, Hyduk SJ, Cybulsky MI. α 4 β 1 integrin/VCAM-1 interaction activates α L β 2 integrinmediated adhesion to ICAM-1 in human T cells. J Immunol. 2000;164(2):746-753.
29. Huang C, Zang Q, Takagi J, Springer TA. Structural and functional studies with antibodies to the integrin beta 2 subunit. A model for the I-like domain. J Biol Chem. 2000;275(28): 21514-21524.
30. Lu C, Ferzly M, Takagi J, Springer TA. Epitope mapping of antibodies to the C-terminal region of the integrin beta 2 subunit reveals regions that become exposed upon receptor activation. J Immunol. 2001;166(9):5629-5637.
31. Sanchez-Madrid F, Krensky AM, Ware CF, et al. Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci USA. 1982;79(23): 7489-7493.
32. Huang C, Springer TA. Folding of the β-propeller domain of the integrin alphaL subunit is independent of the I domain and dependent on the β2 subunit. Proc Natl Acad Sci USA. 1997;94(7):3162-3167.
33. Petruzzelli L, Maduzia L, Springer TA. Activation of lymphocyte function-associated molecule-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) mimicked by an antibody directed against CD18. J Immunol. 1995;155(2):854-866.
34. Bazil V, Stefanová I, Hilgert I, Kristofová H, Vaněk S, Horejsí V. Monoclonal antibodies against human leucocyte antigens. IV. Antibodies against subunits of the LFA-1 (CD11a/CD18) leucocyteadhesion glycoprotein. Folia Biol (Praha). 1990; 36(1):41-50.
35. Nishida N, Xie C, Shimaoka M, Cheng Y, Walz T, Springer TA. Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity. 2006;25(4):583-594.
36. Chen X, Xie C, Nishida N, Li Z, Walz T, Springer TA. Requirement of open headpiece conformation for activation of leukocyte integrin alphaXbeta2. Proc Natl Acad Sci USA. 2010;107(33): 14727-14732.
37. Drbal K, Angelisová P, Cerný J, Hilgert I, Horejsí V. A novel anti-CD18 mAb recognizes an activation-related epitope and induces a highaffinity conformation in leukocyte integrins. Immunobiology. 2001;203(4):687-698.
38. Tang R-H, Tng E, Law SKA, Tan S-M. Epitope mapping of monoclonal antibody to integrin alphaL beta2 hybrid domain suggests different requirements of affinity states for intercellular adhesion molecules (ICAM)-1 and ICAM-3 binding. J Biol Chem. 2005;280(32):29208-29216.
39. Tan SM, Robinson MK, Drbal K, van Kooyk Y, Shaw JM, Law SK. The N-terminal region and the mid-region complex of the integrin β 2 subunit. J Biol Chem. 2001;276(39):36370-36376.
40. Tng E, Tan SM, Ranganathan S, Cheng M, Law SKA. The integrin α L β 2 hybrid domain serves as a link for the propagation of activation signal from its stalk regions to the I-like domain. J Biol Chem. 2004;279(52):54334-54339.
41. Beals CR, Edwards AC, Gottschalk RJ, Kuijpers TW, Staunton DE. CD18 activation epitopes induced by leukocyte activation. J Immunol. 2001; 167(11):6113-6122.
42. Hildreth JE, Gotch FM, Hildreth PD, McMichael AJ. A human lymphocyte-associated antigen involved in cell-mediated lympholysis. Eur J Immunol. 1983;13(3):202-208.
43. Lu C, Shimaoka M, Salas A, Springer TA. The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1. J Immunol. 2004;173(6):3972-3978.
44. Werther WA, Gonzalez TN, O'Connor SJ, et al. Humanization of an anti-lymphocyte functionassociated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996; 157(11):4986-4995.
45. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol. 2000;42(3):428-435.
46. Jullien D, Prinz JC, Langley RGB, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology. 2004;208(4):297-306.
47. Leitinger B, Hogg N. Effects of I domain deletion on the function of the beta2 integrin lymphocyte function-associated antigen-1. Mol Biol Cell. 2000;11(2):677-690.